{
    "clinical_study": {
        "@rank": "159622", 
        "arm_group": [
            {
                "arm_group_label": "Cohort A1, Dose Level 1: CAT 2003 or placebo fasting", 
                "arm_group_type": "Experimental", 
                "description": "Single dose"
            }, 
            {
                "arm_group_label": "Cohort A2, Dose Level 2: CAT 2003 or placebo fasting", 
                "arm_group_type": "Experimental", 
                "description": "Single dose"
            }, 
            {
                "arm_group_label": "Cohort A3, Dose Level 3: CAT 2003 or placebo fasting", 
                "arm_group_type": "Experimental", 
                "description": "Single dose"
            }, 
            {
                "arm_group_label": "Cohort A4, Dose Level 4: CAT 2003 or placebo fasting", 
                "arm_group_type": "Experimental", 
                "description": "Single dose"
            }, 
            {
                "arm_group_label": "Cohort A5, Dose Level 5: CAT 2003 or placebo fasting", 
                "arm_group_type": "Experimental", 
                "description": "Single dose"
            }, 
            {
                "arm_group_label": "Cohort A2: Dose Level 2: CAT 2003 or placebo fed", 
                "arm_group_type": "Experimental", 
                "description": "Single dose"
            }, 
            {
                "arm_group_label": "Cohort A3: Dose level 3:CAT 2003 or placebo fed", 
                "arm_group_type": "Experimental", 
                "description": "Single dose"
            }, 
            {
                "arm_group_label": "Cohort B1: Dose level 6: CAT 2003 or placebo", 
                "arm_group_type": "Experimental", 
                "description": "Multiple dose for 14 days"
            }, 
            {
                "arm_group_label": "Cohort B2: Dose level 7: CAT 2003 or placebo", 
                "arm_group_type": "Experimental", 
                "description": "Multiple dose for 14 days"
            }, 
            {
                "arm_group_label": "Cohort B3: Dose level 8: CAT 2003 or placebo", 
                "arm_group_type": "Experimental", 
                "description": "Multiple dose for 14 days"
            }, 
            {
                "arm_group_label": "Cohort B4: Dose level 9: CAT 2003 or placebo", 
                "arm_group_type": "Experimental", 
                "description": "Multiple dose for 14 days"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a two-part Phase 1 placebo-controlled, double-blind, randomized single and multiple\n      ascending dose study. In Part A, CAT-2003 is administered as a single dose; at two doses\n      (1000 and 2000 mg), subjects will return for a second dose of CAT-2003 or placebo after a\n      high fat meal. In Part B, CAT-2003 is administered for 14 consecutive days."
        }, 
        "brief_title": "A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Dyslipidemia", 
        "condition_browse": {
            "mesh_term": "Dyslipidemias"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Major Inclusion Criteria:\n\n          -  Provision of written informed consent prior to any study-specific procedure;\n\n          -  Good health as determined by medical history, physical examination, vital signs, ECG,\n             and clinical laboratory measurements;\n\n          -  Satisfies one of the following:\n\n               1. Females not of childbearing potential: non-pregnant and non-lactating;\n                  surgically sterile or postmenopausal for 2 years or at least 1 year with a\n                  follicle stimulating hormone assessment (FSH) greater than or equal to 40 IU/L;\n                  OR\n\n               2. Males: surgically sterile, abstinent, or subject or partner is utilizing an\n                  acceptable contraceptive method during and 3 months after the last study dose;\n\n        Major Exclusion Criteria:\n\n          -  Clinically significant disease that requires a physician's care and/or would\n             interfere with study evaluations\n\n          -  Clinically significant electrocardiogram (ECG) abnormalities or laboratory results as\n             assessed by the investigator, such as QTcF >450;\n\n          -  Use of any investigational drug or participation in any investigational study within\n             30 days prior to screening or 5 half-lives of the study agent, whichever is longer;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "99", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01725594", 
            "org_study_id": "CAT-2003-101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort A1, Dose Level 1: CAT 2003 or placebo fasting", 
                    "Cohort A2, Dose Level 2: CAT 2003 or placebo fasting", 
                    "Cohort A3, Dose Level 3: CAT 2003 or placebo fasting", 
                    "Cohort A4, Dose Level 4: CAT 2003 or placebo fasting", 
                    "Cohort A5, Dose Level 5: CAT 2003 or placebo fasting", 
                    "Cohort A2: Dose Level 2: CAT 2003 or placebo fed", 
                    "Cohort A3: Dose level 3:CAT 2003 or placebo fed", 
                    "Cohort B1: Dose level 6: CAT 2003 or placebo", 
                    "Cohort B2: Dose level 7: CAT 2003 or placebo", 
                    "Cohort B3: Dose level 8: CAT 2003 or placebo", 
                    "Cohort B4: Dose level 9: CAT 2003 or placebo"
                ], 
                "intervention_name": "CAT 2003", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort A1, Dose Level 1: CAT 2003 or placebo fasting", 
                    "Cohort A2, Dose Level 2: CAT 2003 or placebo fasting", 
                    "Cohort A3, Dose Level 3: CAT 2003 or placebo fasting", 
                    "Cohort A4, Dose Level 4: CAT 2003 or placebo fasting", 
                    "Cohort A5, Dose Level 5: CAT 2003 or placebo fasting", 
                    "Cohort A2: Dose Level 2: CAT 2003 or placebo fed", 
                    "Cohort A3: Dose level 3:CAT 2003 or placebo fed", 
                    "Cohort B1: Dose level 6: CAT 2003 or placebo", 
                    "Cohort B2: Dose level 7: CAT 2003 or placebo", 
                    "Cohort B3: Dose level 8: CAT 2003 or placebo", 
                    "Cohort B4: Dose level 9: CAT 2003 or placebo"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "July 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio"
                }, 
                "name": "Medpace CPU"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "11", 
        "official_title": "A Two-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003 in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Medpace, Inc.", 
            "last_name": "Lukasz Biernat, M.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Frequency and severity of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Screening to End of study (up to 4 weeks following randomization)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01725594"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "AUCinf of CAT-2003", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 7 and 14"
            }, 
            {
                "measure": "Cmax of CAT-1004", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 7 and14"
            }, 
            {
                "measure": "Changes from baseline for hematology, chemistry, coagulation and urinalysis", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through End of study (up to 4 weeks)"
            }, 
            {
                "measure": "Changes from baseline for Physical exams", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through end of study (up to 4 weeks)"
            }, 
            {
                "measure": "Changes from baseline for ECGs", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through end of study (up to 4 weeks)"
            }, 
            {
                "measure": "Changes from baseline in vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through end of study (up to 4 weeks)"
            }, 
            {
                "measure": "Assess the pharmacodynamic effects of multiple doses of CAT-2003 on triglycerides and other lipids (LDL-C, VLDL-C, VLDL-triglycerides, non-HDL-C, total cholesterol, HDL-C), apoB, lipoprotein(a), and PCSK9 in healthy subjects with mild dyslipidemia", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of study (up to 4 weeks)"
            }
        ], 
        "source": "Catabasis Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Catabasis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}